US-based biotechnology company Imunon has reported positive results from its Phase II OVATION 2 trial of IMNN-001 for ovarian ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Momentum Continues with Presentations at ASCO and ESMO Imunon, Inc.

Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response  Results, presented simultaneously in oral ...

IMUNON reports promising Phase 2 results for IMNN-001 in ovarian cancer, presenting at ASCO 2025 and publishing in Gynecologic Oncology. IMUNON, Inc. has announced significant progress in cancer ...

As I mark my first year as President and CEO of IMUNON, I am thrilled to share the progress we have made in advancing our mission to transform cancer treatment. With robust fundamentals and ...

Progress with IMNN-001: A Potential Game-Changer for Ovarian Cancer Over the past year, we have achieved remarkable milestones, most notably with our lead candidate, IMNN-001, which has entered ...

Over the past year, we have achieved remarkable milestones, most notably with our lead candidate, IMNN-001, which has entered the pivotal Phase 3 OVATION 3 Study for the frontline treatment of women ...